Findings include exclusion of people with cognitive, visual, hearing, mobility, and other disabilities, without documented justification
FRIDAY, Oct. 14, 2022 (HealthDay News) — People with disabilities are commonly excluded from clinical trials, according to a report published in the October issue of Health Affairs.
Willyanne DeCormier Plosky, Ph.D., from Brigham and Women’s Hospital in Boston, and colleagues analyzed 97 recent interventional protocols in four therapeutic areas registered on ClinicalTrials.gov to assess disability status of trial participants.
The researchers found that 85 percent of protocols allowed broad investigator discretion to determine eligibility, whereas only 18 percent explicitly permitted people with disabilities to use forms of support (e.g., supported decision making or assistive devices) to facilitate study participation. Eligibility criteria limiting participation of people with disabilities included exclusions for psychiatric (68 percent), substance use (62 percent), HIV or hepatitis (53 percent), cognitive or intellectual (42 percent), visual (34 percent), hearing (10 percent), mobility (9 percent), long-term care (6 percent), and speech and communication (3 percent) disability-related domains. Only 24 percent of these exclusions provided documented justification.
“We recommend greater scrutiny of study eligibility criteria, scientific or ethical justification of exclusions, and accessible study design,” the authors write.
One author disclosed financial ties to the Takeda Pharmaceuticals Ethics Advisory Council.
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities
Most Adults With Moderate-to-Severe Ulcerative Colitis Ineligible for RCTs
Huge Gap Exists Between Regulatory Authorization, Clinical Validation of AI Medical Devices
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
Barriers to Pediatric Cancer Clinical Trial Participation Identified
Povorcitinib Beneficial for Moderate-to-Severe Hidradenitis Suppurativa